All In Biotech

Drug Trial Radar · NCT04140227

Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)

A Phase 3, Multi-Center, Open-Label, Single-Arm Extension Clinical Trial to Assess the Extended Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)

Last checked: Nov 20, 2026Latest source record: Mar 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

256

Actual

Start

Sep 24, 2020

Primary completion

Jan 5, 2022

Study completion Jan 5, 2022

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Oct 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this trial are to evaluate the safety and tolerability of perfluorohexyloctane (NOV03) ophthalmic solution during long-term use in subjects with Dry Eye Disease (DED) associated with MGD (Meibomian Gland Dysfunction). Further objective is to evaluate the efficacy of perfluorohexyloctane (NOV03) solution during long-term use in subjects with DED associated with MGD.

Conditions

  • Dry Eye Disease (DED)

Interventions

  • NOV03Drug

    100% Perfluorohexyloctane

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Ocular and Non-ocular Adverse EventsTime frame: 12 months

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Bausch Site 124

    Birmingham, Alabama

  • Bausch Site 125

    Scottsdale, Arizona

  • Bausch Site 110

    Glendale, California

  • Bausch Site 121

    Long Beach, California

  • Bausch Site 102

    Mission Hills, California

  • Bausch Site 101

    Newport Beach, California

  • Bausch Site 116

    Rancho Cordova, California

  • Bausch Site 103

    Torrance, California

  • Bausch Site 123

    Torrance, California

  • Bausch Site 127

    Danbury, Connecticut

  • Bausch Site 129

    Fort Myers, Florida

  • Bausch Site 115

    Jacksonville, Florida

  • Bausch Site 106

    Largo, Florida

  • Bausch Site 117

    Tampa, Florida

  • Bausch Site 108

    Lake Villa, Illinois

  • Bausch Site 112

    Indianapolis, Indiana

  • Bausch Site 119

    Edgewood, Kentucky

  • Bausch Site 126

    Winchester, Massachusetts

  • Bausch Site 113

    Kansas City, Missouri

  • Bausch Site 111

    St Louis, Missouri

  • Bausch Site 128

    Slingerlands, New York

  • Bausch Site 114

    Raleigh, North Carolina

  • Bausch Site 122

    Cranberry Township, Pennsylvania

  • Bausch Site 107

    Memphis, Tennessee

  • Bausch Site 109

    Nashville, Tennessee

  • Bausch Site 120

    El Paso, Texas

  • Bausch Site 104

    Lakeway, Texas

  • Bausch Site 118

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.